Finding biological markers to improve care for spinal muscular atrophy
Part of Brain & nervous system clinical trials.
This study looks for natural substances in the blood that may help doctors better understand and treat spinal muscular atrophy. It involves blood samples and other biological specimens from patients with SMA, including newborns detected through screening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of spinal muscular atrophy (SMA) with a known change in the SMN1 gene.
- For newborns: SMA was found through newborn screening and the diagnosis was genetically confirmed.
- A parent or legal guardian must agree to let the patient take part in the study.
- You are willing to give blood samples and other biological samples as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at changes in two genes, SMN1 and SMN2, which are linked to spinal muscular atrophy (SMA). It aims to better understand the different versions of these genes in healthy people and those with SMA. Participating involves a blood sample and genetic analysis.
This trial tests a new medicine called EXG001-307 for babies with spinal muscular atrophy (SMA) types 1 and 2. The goal is to see if it is safe and helps with muscle strength and breathing.
This trial tests a one-time gene therapy given through a vein to add a working SMN gene in children with spinal muscular atrophy (SMA). It mainly looks at safety first, and also checks early signs that treatment helps the disease.
This study uses wearable devices (like smartwatches or activity trackers) to monitor movement and motor development in young children with spinal muscular atrophy (SMA), a rare genetic condition affecting muscle strength. The goal is to see if wearables can track disease progression and treatment response better than traditional clinic visits.
This trial tests whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) is safe and tolerable for people with spinal muscular atrophy (SMA). It may help improve muscle function by activating low motor neurons.
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
Hear when a new Spinal Muscular Atrophy (SMA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.